UM  > Faculty of Health Sciences
Residential Collegefalse
Status已發表Published
Targeting the AKT-P53/CREB pathway with epicatechin for improved prognosis of traumatic brain injury
Wang,Ziheng1,2,3; Lu,Zhichao1,2; Chen,Yixun2,4; Wang,Chenxing1,2; Gong,Peipei1; Jiang,Rui1; Liu,Qianqian1
2024-02
Source PublicationCNS NEUROSCIENCE & THERAPEUTICS
ISSN1755-5930
Volume30Issue:2Pages:e14364
Abstract

Aims: The aim of this study was to evaluate the effect of epicatechin, on neurological recovery and neuroinflammation after traumatic brain injury (TBI) to investigate its potential value in clinical practice.

Methods: TBI model was established in adult rats by CCI method. The effect of epicatechin was evaluated after intraperitoneal injection. Neurological recovery after TBI was assessed by Morris Water Maze, mNSS score, Rotarod test and Adhesive removal test. Protein and gene expression was assessed by Western blot, ELISA, PCR and immunofluorescence. Furthermore, the use of AKT pathway inhibitors blocked the therapeutic effects of epicatechin clarifying AKT-P53/CREB as a potential pathway for the effects of epicatechin.

Results: Administering epicatechin after TBI prevented neuronal death, reduced neuroinflammation, and promoted neurological function restoration in TBI rats. Network pharmacology study suggested that epicatechin may exert its therapeutic benefits through the AKT-P53/CREB pathway.

Conclusion: These results indicate that epicatechin, a monomeric compound derived from tea polyphenols, possesses potent antioxidant and anti-inflammatory properties after TBI. The mechanism may be related to the regulation of the AKT-P53/CREB signal pathway.

KeywordEpicatechin Inflammation Microglia Neurological Function Traumatic Brain Injury
DOI10.1111/cns.14364
URLView the original
Indexed BySCIE
Language英語English
WOS Research AreaNeurosciences & Neurology ; Pharmacology & Pharmacy
WOS SubjectNeurosciences ; Pharmacology & Pharmacy
WOS IDWOS:001030795300001
PublisherWILEY, 111 RIVER ST, HOBOKEN 07030-5774, NJ
Scopus ID2-s2.0-85165361724
Fulltext Access
Citation statistics
Document TypeJournal article
CollectionFaculty of Health Sciences
Centre for Precision Medicine Research and Training
Corresponding AuthorGong,Peipei; Jiang,Rui; Liu,Qianqian
Affiliation1.Department of Neurosurgery,Affiliated Hospital of Nantong University,Medical School of Nantong University,Nantong,China
2.Research Center of Clinical Medicine,Affiliated Hospital of Nantong University,Nantong,China
3.Centre for Precision Medicine Research and Training, Faculty of Health Sciences, University of Macau,Macao
4.Eye Institute,Affiliated Hospital of Nantong University,Medical School of Nantong University,Nantong,China
First Author AffilicationFaculty of Health Sciences
Recommended Citation
GB/T 7714
Wang,Ziheng,Lu,Zhichao,Chen,Yixun,et al. Targeting the AKT-P53/CREB pathway with epicatechin for improved prognosis of traumatic brain injury[J]. CNS NEUROSCIENCE & THERAPEUTICS, 2024, 30(2), e14364.
APA Wang,Ziheng., Lu,Zhichao., Chen,Yixun., Wang,Chenxing., Gong,Peipei., Jiang,Rui., & Liu,Qianqian (2024). Targeting the AKT-P53/CREB pathway with epicatechin for improved prognosis of traumatic brain injury. CNS NEUROSCIENCE & THERAPEUTICS, 30(2), e14364.
MLA Wang,Ziheng,et al."Targeting the AKT-P53/CREB pathway with epicatechin for improved prognosis of traumatic brain injury".CNS NEUROSCIENCE & THERAPEUTICS 30.2(2024):e14364.
Files in This Item:
There are no files associated with this item.
Related Services
Recommend this item
Bookmark
Usage statistics
Export to Endnote
Google Scholar
Similar articles in Google Scholar
[Wang,Ziheng]'s Articles
[Lu,Zhichao]'s Articles
[Chen,Yixun]'s Articles
Baidu academic
Similar articles in Baidu academic
[Wang,Ziheng]'s Articles
[Lu,Zhichao]'s Articles
[Chen,Yixun]'s Articles
Bing Scholar
Similar articles in Bing Scholar
[Wang,Ziheng]'s Articles
[Lu,Zhichao]'s Articles
[Chen,Yixun]'s Articles
Terms of Use
No data!
Social Bookmark/Share
All comments (0)
No comment.
 

Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.